European Union Approves Merck's Hepatitis C Drug Victrelis
July 20, 2011
Merck & Co. said Monday that EU regulators have approved its drug Victrelis (boceprevir). The drug is administered along with standard combination therapy to treat hepatitis C; the approval is for use in treatment-naive patients as well as those who have failed on other regimens. Victrelis now can be marketed in all 27 EU countries. US regulators approved Victrelis on May 13.
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)